FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Categories Genetic Testing
Study : Do Vitamin B supplements alter breast cancer risk for women with BRCA mutations?
Most relevant for: High risk women with a BRCA1 or BRCA2 mutation
Vitamins are an essential part of our diet. Vitamin supplements are often used to improve general health. This study explores how vitamin B supplements may affect breast cancer risk in women with BRCA mutations. (5/17/19)
Read More
Relevance: Medium-High
Research Timeline: Post Approval
Guideline : Breast surgeons recommend genetic testing for all breast cancer patients
Most relevant for: Anyone diagnosed with breast cancer
The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Gaps in information about breast cancer risk and prevention impact African American women
Most relevant for: African American women who are at high risk for breast cancer
A study showed that African American women with increased breast cancer risk experienced greater burdens in obtaining information at each step compared to white women. Racial differences in preventive choices correlated with differences in information and provider access. (3/14/19)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Prevalence of BRCA founder mutations in Bahamian women
Most relevant for: Bahamanian women
The Bahamas has the highest known frequency of BRCA mutations among people diagnosed with breast cancer. This study reviewed whether population-based BRCA testing (testing everyone regardless of family or personal history of cancer) would be an effective approach for finding mutation carriers in the Bahamas. (3/4/19)
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Inherited breast cancer in Nigerian women
Most relevant for: Nigerian women or women of Nigerian descent who have breast cancer
A new study shows that among Nigerian women, one in eight cases of breast cancer is due to an inherited mutation in BRCA1, BRCA2, PALB2 or TP53. (12/5/18)
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Can population-based DNA sequencing find more people at risk for hereditary cancers?
Most relevant for: Women over age 30
It is well documented that many BRCA mutation carriers are missed using current family history-based screening approaches. As a result, experts are beginning to call for population-based BRCA genetic testing—an organized effort to screen all women like we do for breast and cervical cancer. A recent study looked at whether a population-based genetic testing approach would better identify mutation carriers compared with current practice. (11/17/18)
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Surgeon attitude impacts rate of genetic testing after a breast cancer diagnosis
Most relevant for: Young women diagnosed with breast cancer who have not yet had genetic testing
A study in JAMA Surgery this year examined the factors that impact genetic testing after a breast cancer diagnosis. This study suggests that the attitudes of attending surgeons about genetic testing have the most impact on whether patients receive testing. (10/6/18)
Read More
Relevance: Medium-Low
Strength of Science: Medium
Research Timeline: Human Research
Study : A new method for determining whether genetic variants in BRCA1 increase cancer risk
Most relevant for: People who have a Variant of Uncertain Significance in a gene associated with cancer risk.
Ever since BRCA1 was discovered, researchers have been trying to understand which of the thousands of possible DNA changes in this gene increase cancer risk and which are harmless changes. A new study in Nature reports how a cutting-edge technology called “genome editing” may be used to classify changes—known as variants of uncertain significance-in BRCA1 as harmful or harmless. Once validated, this same technology may be used to classify variants in other genes. (9/29/18)
Read More
Relevance: Medium-High
Quality of Writing: Medium-High
Article : Cancer experience in families affects decision making
Most relevant for: Women with an inherited mutation linked to increased risk for cancer
Women with inherited mutations in genes that increase breast and ovarian cancer risk have an additional challenge: coping with how those mutations impact their families and how a family member’s cancer experience can shape their own perception. In a recent U.S. News and World Report article, Elaine Howley explores how a woman's decisions about healthcare, cancer prevention and treatment are affected by experience with cancer in the family. (9/25/18)
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation
Most relevant for: Women with BRCA1 mutations who have had risk-reducing ovary removal and have never been diagnosed with breast cancer
Does hormone therapy (HT) alter the risk of breast cancer for woman carrying a BRCA1 mutation who have never been diagnosed with cancer? In this study, researchers showed that among women with BRCA1 mutations, HT use did not increase breast cancer rates for 10 years after ovary removal. More women taking combined estrogen plus progesterone developed breast cancer compared to those taking estrogen only, though this difference was not statistically significant. (9/7/18)
